Literature DB >> 18048647

ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.

Liguang Chen1, Lang Huynh, John Apgar, Li Tang, Laura Rassenti, Arthur Weiss, Thomas J Kipps.   

Abstract

We transduced chronic lymphocytic leukemia (CLL) cells lacking ZAP-70 with vectors encoding ZAP-70 or various mutant forms of ZAP-70 and monitored the response of transduced CLL cells to treatment with F(ab)(2) anti-IgM (anti-mu). CLL cells made to express ZAP-70, a kinase-defective ZAP-70 (ZAP-70-KA(369)), or a ZAP-70 unable to bind c-Cbl (ZAP-YF(292)) experienced greater intracellular calcium flux and had greater increases in the levels of phosphorylated p72(Syk), B-cell linker protein (BLNK), and phospholipase C-gamma, and greater activation of the Ig accessory molecule CD79b in response to treatment with anti-mu than did mock-transfected CLL cells lacking ZAP-70. Transfection of CLL cells with vectors encoding truncated forms of ZAP-70 revealed that the SH2 domain, but not the SH1 domain, was necessary to enhance intracellular calcium flux in response to treatment with anti-mu. We conclude that ZAP-70 most likely acts as an adapter protein that facilitates B-cell receptor (BCR) signaling in CLL cells independent of its tyrosine kinase activity or its ability to interact with c-Cbl.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18048647      PMCID: PMC2254551          DOI: 10.1182/blood-2006-12-062265

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain.

Authors:  A C Chan; M Iwashima; C W Turck; A Weiss
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

2.  Reconstitution of Syk function by the ZAP-70 protein tyrosine kinase.

Authors:  G H Kong; J Y Bu; T Kurosaki; A S Shaw; A C Chan
Journal:  Immunity       Date:  1995-05       Impact factor: 31.745

3.  Differential intrinsic enzymatic activity of Syk and Zap-70 protein-tyrosine kinases.

Authors:  S Latour; L M Chow; A Veillette
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

4.  p120cbl is a major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc adaptors, and the p85 subunit of phosphatidylinositol 3-kinase.

Authors:  G Panchamoorthy; T Fukazawa; S Miyake; S Soltoff; K Reedquist; B Druker; S Shoelson; L Cantley; H Band
Journal:  J Biol Chem       Date:  1996-02-09       Impact factor: 5.157

Review 5.  Immunoglobulin genes in chronic lymphocytic leukemia.

Authors:  T J Kipps
Journal:  Blood Cells       Date:  1993

6.  Enhancement of lymphocyte responsiveness by a gain-of-function mutation of ZAP-70.

Authors:  Q Zhao; A Weiss
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

7.  Differential expression of ZAP-70 and Syk protein tyrosine kinases, and the role of this family of protein tyrosine kinases in TCR signaling.

Authors:  A C Chan; N S van Oers; A Tran; L Turka; C L Law; J C Ryan; E A Clark; A Weiss
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

8.  Molecular cloning of human Syk. A B cell protein-tyrosine kinase associated with the surface immunoglobulin M-B cell receptor complex.

Authors:  C L Law; S P Sidorenko; K A Chandran; K E Draves; A C Chan; A Weiss; S Edelhoff; C M Disteche; E A Clark
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

9.  Dominant-negative zeta-associated protein 70 inhibits T cell antigen receptor signaling.

Authors:  D Qian; M N Mollenauer; A Weiss
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

10.  Association of tyrosine protein kinase Zap-70 with the protooncogene product p120c-cbl in T lymphocytes.

Authors:  M Fournel; D Davidson; R Weil; A Veillette
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  63 in total

Review 1.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

Review 2.  ZAP-70: an essential kinase in T-cell signaling.

Authors:  Haopeng Wang; Theresa A Kadlecek; Byron B Au-Yeung; Hanna E Sjölin Goodfellow; Lih-Yun Hsu; Tanya S Freedman; Arthur Weiss
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05       Impact factor: 10.005

3.  Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.

Authors:  Davorka Messmer; Jessie-F Fecteau; Morgan O'Hayre; Ila S Bharati; Tracy M Handel; Thomas J Kipps
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

4.  Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.

Authors:  Bing Xia; Fulian Qu; Tian Yuan; Yizhuo Zhang
Journal:  Oncol Lett       Date:  2015-10-13       Impact factor: 2.967

Review 5.  How will B-cell-receptor-targeted therapies change future CLL therapy?

Authors:  Jeffrey A Jones; John C Byrd
Journal:  Blood       Date:  2014-01-06       Impact factor: 22.113

Review 6.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

Review 7.  Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Lars Rönnstrand
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

8.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

9.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Nicole Weit; Nils Lilienthal; Michael Hallek; Michael J Keating; Dan Jones
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

10.  Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

Authors:  Suping Zhang; Christina C N Wu; Jessie-F Fecteau; Bing Cui; Liguang Chen; Ling Zhang; Rongrong Wu; Laura Rassenti; Fitzgerald Lao; Stefan Weigand; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.